青光眼药物的疗效与药物相互作用:系统评价与组件网络荟萃分析
该系统评价与组件网络荟萃分析纳入166项随机对照试验共36494例原发性开角型青光眼或高眼压症患者,评估各类局部降眼压药物单药及联合方案的疗效与相互作用。结果显示,前列腺素F2α类似物(PGFA)为基础的联合方案降眼压幅度最大,其中PGFA联合碳酸酐酶抑制剂(CAI)排名最高;单药中一氧化氮供体前列腺素类似物(NO-PGA)最有效。组件网络荟萃分析发现PGFA联合β受体阻滞剂或ROCK抑制剂存在拮抗作用,而PGFA联合CAI表现为协同作用。
要点
- PGFA为基础的联合方案降眼压幅度最大(范围-7.41至-5.81 mmHg,证据确定性低),PGFA联合CAI排名最高。
- 单药中NO-PGA最有效(-5.15 mmHg,95%CI -6.18至-4.11,证据确定性低),其次为PGFA(-4.75 mmHg,证据确定性高)和EP2激动剂(-3.50 mmHg,证据确定性高)。
- 组件网络荟萃分析显示PGFA联合BAB(1.26 mmHg)和PGFA联合ROCKI(0.84 mmHg)存在拮抗,PGFA联合CAI(-2.05 mmHg)存在协同。
核心结论
- 非PGFA为基础的三联方案和PGFA为基础的联合方案,尤其是PGFA联合CAI,是最有效的。
- EP2激动剂优于其他非PGFA治疗,但排名低于PGFA和NO-PGA。
- PGFA联合BAB或ROCKI显示拮抗作用,而PGFA联合CAI的协同作用提示了新联合方案的有前景方向。
研究设计与样本
- 系统评价与组件网络荟萃分析,检索Embase和PubMed截至2025年5月20日,纳入比较局部青光眼药物降眼压效应的随机对照试验,研究对象为原发性开角型青光眼或高眼压症患者。
- 纳入166项试验共36494例参与者,评估药物包括PGFA、NO-PGA、EP2激动剂、乌诺前列酮、α2肾上腺素能激动剂(AAA)、β肾上腺素能阻滞剂(BAB)、碳酸酐酶抑制剂(CAI)、ROCKI及其联合方案。
- 采用基于对比的频率学派随机效应模型网络荟萃分析计算降眼压加权均数差,使用P分数确定排名,采用Cochrane偏倚风险工具评估偏倚风险,使用CINeMA评估证据确定性,组件网络荟萃分析探索药物间相互作用,研究注册号CRD42024573926。
主要发现
- PGFA为基础的联合方案降眼压幅度最大(范围-7.41至-5.81 mmHg;证据确定性低),其中PGFA联合CAI排名最高。
- 单药中NO-PGA最有效(-5.15 mmHg,95%CI -6.18至-4.11;证据确定性低),其次为PGFA(-4.75 mmHg,95%CI -5.19至-4.31;证据确定性高)和EP2激动剂(-3.50 mmHg,95%CI -4.27至-2.73;证据确定性高)。
- ROCKI(-3.24 mmHg,95%CI -3.85至-2.63;证据确定性高)与AAA(-3.36 mmHg,95%CI -3.85至-2.86;证据确定性高)和BAB(-3.29 mmHg,95%CI -3.71至-2.87;证据确定性高)相当。
- 非PGFA为基础的二联方案(范围-5.10至-4.82 mmHg;证据确定性低至高)与PGFA相当,而非PGFA为基础的三联方案(AAA联合BAB联合CAI,-7.22 mmHg,95%CI -9.04至-5.40;证据确定性低)与排名最高的PGFA为基础联合方案相似。
- 组件网络荟萃分析显示PGFA联合BAB存在拮抗(1.26 mmHg),PGFA联合ROCKI存在拮抗(0.84 mmHg),而PGFA联合CAI存在协同(-2.05 mmHg)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TOPIC: To investigate the efficacy of monotherapies and combinations of glaucoma medications in reducing intraocular pressure (IOP) and drug interactions. CLINICAL RELEVANCE: The relative treatment efficacy and interaction of the newly introduced E-prostanoid receptor 2 (EP2) agonists, rho-kinase inhibitors (ROCKIs), and various combination therapies remain unknown. METHODS: Embase and PubMed were searched through May 20, 2025, for randomized controlled trials comparing IOP-lowering effects of topical glaucoma medications in patients with primary open-angle glaucoma or ocular hypertension. The medications evaluated included prostaglandin F2α analogs (PGFAs), nitric oxide-donating prostaglandin analogs (NO-PGA), EP2 agonists, unoprostone, α2-adrenergic agonists (AAAs), β-adrenergic blockers (BABs), carbonic anhydrase inhibitors (CAIs), ROCKIs, and their combinations. A network meta-analysis (NMA) using contrast-based frequentist random-effects models calculated the weighted mean difference in IOP reduction, with rankings determined using P scores. The risk of bias was assessed with Cochrane Risk of Bias Tool, and the certainty of evidence (COE) was evaluated using confidence in network meta-analysis. Component NMA explored interactions between different medications. The study was registered with the International Prospective Register of Systematic Reviews (identifier, CRD42024573926). RESULTS: Among 166 trials (36 494 participants), PGFA-based combinations demonstrated the greatest IOP reduction (range, -7.41 to -5.81 mmHg; COE: low), with PGFAs plus CAIs ranking highest. Among monotherapies, NO-PGA was most effective (-5.15 [95% confidence interval: -6.18 to -4.11 mmHg]; COE: low), followed by PGFA (-4.75 [-5.19 to -4.31]; high) and EP2 agonist (-3.50 [-4.27 to -2.73]; high). ROCKIs (-3.24 [-3.85 to -2.63]; high) were comparable with AAA (-3.36 [-3.85 to -2.86]; high) and BAB (-3.29 [-3.71 to -2.87]; high). Non-PGFA-based dual combinations (range, -5.10 to -4.82 mmHg; low to high) were comparable to PGFA, whereas non-PGFA-based triple combinations (AAA plus BAB plus CAI, -7.22 [-9.04 to -5.40]; low) were similar to the top-ranking PGFA-based combinations. Component NMA revealed antagonism between PGFA plus BAB (1.26 mmHg) and PGFA plus ROCKI (0.84), whereas synergy was observed with PGFA plus CAI (-2.05). DISCUSSION: Non-PGFA-based triple combinations and PGFA-based combinations, especially PGFA plus CAI, were the most effective. E-prostanoid receptor 2 agonists outperformed other non-PGFA treatments but ranked below PGFA and NO-PGA. Prostaglandin F2α analog plus BAB or ROCKI showed antagonism, whereas the synergy of PGFA plus CAI suggested a promising avenue for new combinations. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
引用
- Hsia Y, Wang C, Su CC, et al. Efficacy and Drug Interactions of Glaucoma Medications: A Systematic Review and Component Network Meta-analysis. Ophthalmology. 2025. PMID: 40701331. doi:10.1016/j.ophtha.2025.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。